Brief: Zymeworks And Royalty Pharma Enter Into $250 Million Royalty-Backed Note Financing
02/03/2026 14:04
March 2 (Reuters) - Royalty Pharma PLC RPRX.O: ZYMEWORKS AND ROYALTY PHARMA ENTER INTO $250 MILLION ROYALTY-BACKED NOTE FINANCING ZYMEWORKS INC - CO TO RETAIN 70% OF ZIIHERA ROYALTIES Source text: ID:nGNX7tKtn2 Further company coverage: RPRX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Royalty Pharma
See all newsAnalysis: Revolution Medicines' Europe efforts signal solo launch ambitions for cancer drug
U.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple
Royalty Pharma falls after Novartis' cholesterol drug fails in study
Brief: Royalty Pharma Announces Update On Novartis’ Phase 3 Topline Results For Pelacarsen
Teva's immune disorder drug meets main goal in mid-stage trial (updated)